Genzyme Officially Rejects Sanofi-Aventis's Public Bid - DailyFinance

One of the most interesting merger and acquisition sagas of the past month is no doubt the French drugmaker Sanofi-Aventis' (SNY) courtship of rare-disease biotech Genzyme (GENZ). On Monday, Genzyme has confirmed that it has received ...

Publish Date: 08/30/2010 8:26

http://www.dailyfinance.com/story/investing/genzyme-officially-rejects-sanofi-aventiss-public-69-bid/19613042/

Sanofi's Bid Is Plea to See Genzyme Books - NYTimes.com

"Let me in, and I might go higher." That, in a nutshell, is the message Chris Viehbacher, the chief executive of Sanofi-Aventis, is sending the management of the biotech company Genzyme in making public his $18.5 billion offer to buy ...

Publish Date: 08/31/2010 7:30

http://dealbook.blogs.nytimes.com/2010/08/31/sanofis-bid-is-plea-to-see-genzyme-books/

Genzyme Shoots Down Sanofi-Aventis's Buyout Offer | Xconomy

Genzyme's board of directors has unanimously rejected a new $18.5 billion buyout bid that came in from French drug giant Sanofi-Aventis over the weekend, saying.

Publish Date: 08/30/2010 9:47

http://www.xconomy.com/boston/2010/08/30/genzyme-shoots-down-sanofi-aventiss-buyout-offer/

Sanofi, Genzyme play chicken over price | Analysis & Opinion |

Let me in and I might go higher. That in a nutshell is the message Sanofi-Aventis chief executive Chris Viehbacher is sending Genzyme's management in making public his $18.5 billion offer to buy the US biotech company.

Publish Date: 08/30/2010 16:31

http://blogs.reuters.com/columns/2010/08/30/sanofi-genzyme-play-chicken-over-price/

No related posts.